Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
AA

Ratings ESG MSCI

Ratings Charles River Laboratories International, Inc.: Strengths and Weaknesses

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
Highlights: Charles River Laboratories International, Inc.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses: Charles River Laboratories International, Inc.
  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • The group shows a rather high level of debt in proportion to its EBITDA.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 74.93 times its estimated earnings per share for the ongoing year.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company appears highly valued given the size of its balance sheet.
  • The company is highly valued given the cash flows generated by its activity.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.

Rating Financials

Charles River Laboratories International, Inc. SectorSwitzerland

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

-

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Charles River Laboratories International, Inc. SectorSwitzerland

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

-

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Charles River Laboratories International, Inc. SectorSwitzerland

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Charles River Laboratories International, Inc. SectorSwitzerland

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Charles River Laboratories International, Inc. SectorSwitzerland

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
13.37B
AA
48.42B
AAA
43.66B -
B
- -
39.51B -
38.95B
AAA
32.61B
A
16.15B
BBB
16.32B - - - -
14.16B
AA
13.37B
AA
Average 27.65B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. CRL Stock
  4. RV6 Stock
  5. Ratings Charles River Laboratories International, Inc.